Mochida Pharmaceutical

4534.TPhase 3

Founded in 1895, Mochida Pharmaceutical is a long-standing Japanese pharmaceutical company focused on the research, development, and commercialization of innovative medicines and healthcare products. The company operates across three core segments: Prescription Pharmaceuticals, Consumer Healthcare (OTC), and Diagnostics. Its strategy combines the lifecycle management of its established revenue-generating products with targeted R&D in areas such as oncology, immunology, and rare diseases to drive future growth.

Market Cap

$353.2M

Employees

1,000-5,000

Focus

Biotech

4534.T · Stock Price

USD 2430.00+1035.00 (+74.19%)

Historical price data

AI Company Overview

Technology Platform

Mochida's R&D is based on applied pharmaceutical sciences including formulation technology and drug delivery systems, supplemented by strategic in-licensing of novel therapeutic candidates.

Pipeline Snapshot

15 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease	Approved
FYU-981 + Febuxostat	Hyperuricemia With or Without Gout	Phase 3
FYU-981	Hyperuricemia With or Without Gout	Phase 3
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)	Hypertriglyceridemia	Phase 3
Enbrel + LBEC0101	Arthritis, Rheumatoid	Phase 3

Opportunities

Growth opportunities include maximizing sales of recently launched specialty drugs like fostamatinib, advancing the mid-stage dermatology pipeline, and leveraging its strong Japanese commercial platform to in-license additional late-stage international assets for the domestic market.

Risk Factors

Key risks include clinical trial failures in the pipeline, intense competition and government-mandated drug price cuts in Japan, and reliance on successful in-licensing to supplement internal R&D productivity.

Competitive Landscape

Mochida competes with large Japanese pharma peers (Takeda, Daiichi Sankyo) and multinationals. Its differentiation lies in its agility, strong sales network in specific therapeutic areas like dermatology, and a balanced portfolio of prescription, OTC, and diagnostic products that provide revenue stability.

Publications

Patents

Pipeline